Impact of renal lesion size on perioperative and pathologic outcomes in patients undergoing laparoscopic partial nephrectomy.

BACKGROUND AND PURPOSE: The size of renal lesions managed with laparoscopic partial nephrectomy (LPN) has been increasing, especially as surgical volume and experience matures. The objective of this study was to assess the perioperative and pathologic outcomes of LPN when stratifying for size of renal lesion. PATIENTS AND METHODS: A retrospective review of LPN performed at the University of Chicago by a single surgeon (ALS) between October 2002 to July 2007 was performed. Patients (153) were then stratified into three groups according to radiographic diameter of the lesion: < or = 2 cm (group A), 2 to 4 cm (group B), and > or = 4 cm (group C). Perioperative, operative, and pathologic data were compared using analysis of variance and Pearson test. Moreover, serum creatinine and creatinine clearance (Cockcroft-Gault) were assessed postoperatively. RESULTS: With regard to operative parameters, operative time was significantly longer in renal lesions > 2 cm (P = 0.0012), and the need for collecting system repair was also more prevalent as lesion size increased (P < 0.0001). Warm ischemia time was longest with lesions 2 to 4 cm (35.3 min) compared with masses < or = 2 cm (27.2 min; P < 0.001) or > or = 4 cm (30.3 min; P = 0.028). All other variables were similar among the three groups, including the rates of positive surgical margins, complications, estimated blood loss, conversion, and transfusion. Comparison of pathologic data suggests smaller lesions are more likely to be of lower grade compared with larger lesions. Postoperative renal function did not differ among the groups with a mean follow-up of 19.9 months. CONCLUSIONS: Although LPN for renal masses 2 to 4 cm necessitated longer warm ischemia, short-term postoperative renal function was not affected by lesion size. Differences in warm ischemia time cannot be attributed solely to lesion size but are likely influenced by a combination of tumor size, location, and depth. LPN can be performed safely in selected patients with larger renal lesions.

Laparoscopic port-site metastasis in urologic surgery.

PURPOSE: Port-site metastasis has been an increasing concern with the spread of laparoscopy in managing urologic malignancies. The purpose of this study was to provide a current review of port-site metastases reported in the urologic oncology literature, as well as etiologic factors and preventative measures. METHODS: A comprehensive Medline search (up to September 2007; subject headings: "neoplasm seeding," "laparoscopy," "urologic neoplasms") of all case reports and series related to laparoscopic urology surgery for malignant disease was performed. The references for each of these case reports and series were also reviewed for any additional reports of port-site metastases. RESULTS: Only 28 cases of port-site metastases involving urologic malignancies have been reported, with laparoscopic procedures involving upper tract transitional cell carcinoma comprising the majority (11/28 or 39%) of these. Recent reports involving renal cell carcinoma, prostatic carcinoma, and bladder cancer have been published as well. SUMMARY: The incidence of port-site metastases is comparable with that seen following open surgery. The etiology is likely multifactorial, but adhering to proper surgical technique is the most effective preventative strategy.

Urinary and sexual quality of life 1 year following robotic assisted laparoscopic radical prostatectomy.

PURPOSE: We evaluated urinary and sexual quality of life 1 year following robotic laparoscopic radical prostatectomy and identified preoperative variables predictive of a severe decrease from baseline. MATERIALS AND METHODS: Using a prospective robotic laparoscopic radical prostatectomy database we identified patients with greater than 1 year of postoperative followup. The UCLA-PCI SF-36v2 questionnaire was used to evaluate urinary and sexual quality of life before and 1 year after surgery. Severe worsening of the postoperative score was defined as a greater than 1 SD decrease. Demographic and preoperative clinical variables were evaluated along with baseline scores on univariate and multivariate analysis. RESULTS: Between February 2003 and September 2007 a total of 1,225 robotic laparoscopic radical prostatectomies were performed at our center and 361 patients (52%) met inclusion criteria. On multivariate analysis baseline urinary function was the only predictor of significant worsening of urinary function (OR 1.04, p = 0.003). Baseline urinary bother was the only predictor of significant worsening of urinary bother (OR 1.05, p <0.0001). A significant decrease in sexual function was predicted by baseline sexual function (OR 1.03, p = 0.0001), baseline sexual bother (OR 1.03, p = 0.005) and nerve sparing technique (OR 0.31, p = 0.05). Predictors of a significant decrease in sexual bother were also baseline sexual function (OR 1.02, p = 0.0001), baseline sexual bother (OR 1.04, p = 0.0007) and nerve sparing technique (OR 0.38, p = 0.02). ORs indicated that higher baseline scores corresponded to a higher risk of postoperative score worsening. CONCLUSIONS: We found that overall better baseline sexual and urinary scores are associated with better postoperative outcomes. However, the risk of a significant decrease in urinary function, urinary bother, sexual function and sexual bother is higher in patients with better baseline scores. Nerve sparing positively affects sexual function and sexual bother.

Long-term functional and oncological outcomes of patients undergoing sural nerve interposition grafting during robot-assisted laparoscopic radical prostatectomy.

PURPOSE: For men with high-volume or high-grade prostate cancer, wide excision of the ipsilateral neurovascular bundle is commonly performed. The concept of nerve reconstruction is intriguing as a feasible approach to preserve sexual function (SF). We sought to evaluate the functional, pathologic, and oncologic outcomes of men who underwent robot-assisted sural-nerve graft (SNG) interposition. PATIENTS AND METHODS: Between February 2003 and May 2007, 1175 consecutive men underwent robot-assisted laparoscopic radical prostatectomy (RLRP). Database analysis identified 27 men who had SNG: 4 bilateral (BL) and 23 unilateral (UL). SF was prospectively evaluated preoperatively and at 1, 3, 6, 12, and 24 months postoperatively using validated questionnaires. Positive surgical margins (PSMs), biochemical recurrence (BCR), and potency were evaluated. RESULTS: Compared with RLRP patients without SNG, patients with SNG were younger (57.2 v 61.8 years, P=0.02), had a higher Gleason score (P=0.02), and had a higher clinical and pathologic stage (P<0.001 for both). Mean surgical time was significantly longer (349 v 195 min, P<0.001) in patients with SNG. With a mean follow-up of 26.1 months, 11 (47.8%) patients with UL-SNG and zero men with BL-SNG regained potency. No significant difference in SF was observed between UL nerve sparing and no SNG (56%) compared with UL nerve sparing with UL-SNG (P=0.44). Rates of return-to-baseline SF (RTB-SF) at 6, 12, and 24 months were 11%, 36% and 45% for UL-SNG, respectively, which were also comparable to UL nerve sparing only (P>0.05). No patient (0%) in the BL-SNG group ever achieved RTB-SF status at any time point. PSMs were observed in 37% (10/27) of all patients. BCR occurred in nine patients (33.3%), seven of whom had PSM (78%); treatment failure occurred within 6 months of surgery, necessitating androgen deprivation therapy. CONCLUSION: Despite optimism regarding SNG, long-term functional outcomes have been disappointing, particularly for BL nerve interposition. UL-SNG functional outcomes do not appear to improve outcomes when compared with men with UL nerve preservation. With the greater risk of PSM and BCR in patients who are considered candidates for SNG, newer treatment modalities are needed to cure their disease while preserving SF.

Expanding indications for neuromodulation.

Neuromodulation in one form or another has been studied for decades for various disease states. Although its mechanism of action remains un-explained, numerous clinical success stories suggest it is a therapy with efficacy and durability. Controlled studies have led to the approval of sacral neuromodulation for urinary urgency and frequency, urinary retention, and urinary urge incontinence. The future holds hopeful possibilities for the application of neuromodulation, namely in the areas of interstitial cystitis, in-tractable pain syndromes, fecal incontinence and constipation, spinal cord injury, and erectile dysfunction. Neuromodulators have also been used in nonurologic conditions, including chronic headaches and intractable chest pain. In adults and children, in the neurologically intact and neurologically impaired, neuromodulation has been shown to improve the quality of life of those suffering chronic disease states. Neuromodulation is changing the future of urology. Treatment of voiding dysfunction and likely other disorders, such as pelvic pain, sexual dysfunction, and bowel disorders, will no longer rely only on medications that are "OK" or destructive-reconstructive procedures that suffer from significant complications. Rather, by modulating the nerves, the urologists will treat these disorders in a minimally invasive fashion and neuromodulation will become the first-line therapy before any major surgery is undertaken.